We are thrilled to announce that Prof. Dr. Jan van de Winkel, President & CEO of Genmab, will present the keynote opening Utrecht Science Lecture during the 2025 Utrecht Science Week on September 26. As a pioneering scientist and industry leader in antibody-based therapies, Jan van de Winkel has been at the forefront of groundbreaking advancements in immunotherapy, shaping the future of cancer treatment and beyond.
With more than 30 years of experience in therapeutic antibodies, Jan van de Winkel has played a pivotal role in translating cutting-edge science into life-changing medicines. As a co-founder of Genmab, he has led the company’s journey from an ambitious startup to a global end-to-end biotech powerhouse. In addition to his executive role, he holds a professorship in immunotherapy at Utrecht University, contributing to academic research and fostering the next generation of scientific leaders.
In his lecture, titled “Cracking the Code on Cancer and Other Serious Diseases: The Past, Present, and Future of Immunotherapy”, he will explore how immunotherapy is revolutionizing medicine. From early discoveries to today’s breakthroughs in cancer care, he will offer insights into the evolving role of antibody therapies, the next frontiers in biotechnology, and the power of collaboration and AI in driving innovation.
As Utrecht Science Week celebrates its fifth edition, this keynote lecture will highlight Utrecht’s ambition as the “Heart of Health” and the Utrecht Science Park as a unique life sciences ecosystem for cutting-edge research and medical innovation. Join us to gain a front-row perspective on the future of immunotherapy and how partnerships between academia, industry, and healthcare can accelerate progress for patients worldwide. More information about the lecture and the opening of registration will follow soon.